Kyowa Kirin: Ada Patient Finder Suitability Analysis
Confidential -- Ada Cockpit -- March 2026 -- v4 Format
Executive Summary
Kyowa Kirin's portfolio is highly aligned with Ada's Patient Finder value proposition. The company's core franchise -- rare diseases with significant diagnostic delay and underdiagnosis -- is precisely where Ada's AI-powered symptom assessment creates the most value.
| Drug |
Condition |
Tier |
Ada Surface |
Co. Motivation |
Fit Score |
Annual Ada Rev (USA) |
| Crysvita |
XLH |
TIER 1 |
8/10 |
10/10 |
9.0 |
$1.6M -- $9.0M |
| Poteligeo |
CTCL (MF/SS) |
TIER 2 |
6/10 |
7/10 |
6.5 |
$0.2M -- $1.1M |
| Lenmeldy |
MLD |
TIER 3 |
4/10 |
6/10 |
4.5 |
$0.4M -- $1.9M |
| Ziftomenib |
AML (NPM1) |
NO |
2/10 |
5/10 |
3.0 |
N/A |
| Rocatinlimab |
Atopic Dermatitis |
NO |
3/10 |
8/10 |
3.5 |
N/A |
Primary Recommendation: Lead with Crysvita/XLH. This is the anchor deal. Poteligeo/CTCL is a credible add-on. Everything else is noise for now.
$3.2M
Conservative (1% capture)
$9.7M
Base Case (3% capture)
$19.9M
Optimistic (5% capture)
Total annual Ada revenue across all drugs and geographies at maturity
Drug 1: Crysvita (Burosumab) -- XLH & TIO
TIER 1 PRIMARY OPPORTUNITY
SECTION A -- MARKET NUMBERS
USA Market
Prevalence & Undiagnosed Pool
| Metric | Value | Source / Math |
|---|
| XLH prevalence | 1 in 20,000 -- 25,000 | Orphanet, Beck-Nielsen 2009 |
| US population | 335 million | Census 2025 |
| Total XLH patients (US) | ~15,000 | 335M / 22,500 (midpoint) |
| Currently diagnosed/treated | ~5,000 -- 6,000 | ~3,500-4,000 on Crysvita; ~1,500 conventional |
| Undiagnosed (US) | ~9,000 -- 10,000 | 63% underdiagnosis rate |
| Drug-eligible (90% of undiagnosed) | ~8,100 -- 9,000 | Crysvita approved for all ages |
Revenue Per Patient
| Metric | Value |
|---|
| WAC (annual, weight-dependent) | $200,000 -- $390,000 |
| Gross-to-net discount | 15 -- 25% (orphan drug) |
| Net revenue per patient/year | ~$200,000 (blended) |
| Ada fee at 8% | $16,000 / patient |
| Ada fee at 10% | $20,000 / patient |
| Ada fee at 12% | $24,000 / patient |
Ada Revenue Scenarios (USA)
| Capture Rate | Patients Found/Year | Annual Ada Revenue |
|---|
| 1% (conservative) | 81 -- 90 | $1.6M -- $1.8M |
| 3% (base) | 243 -- 270 | $4.9M -- $5.4M |
| 5% (optimistic) | 405 -- 450 | $8.1M -- $9.0M |
Patent / Exclusivity
| Type | Status | Date |
|---|
| US Orphan Drug Exclusivity (XLH) | EXPIRED | April 17, 2025 |
| US BPCIA 12-year biologics data exclusivity | ACTIVE | ~April 2030 |
| Canada patent | ACTIVE | February 14, 2028 |
| EU data exclusivity | ACTIVE | ~February 2028 |
Top Competitors
| Competitor | Product | Market Share |
|---|
| Conventional therapy | Oral phosphate + active vitamin D | ~30% (declining) |
| Ascendis Pharma | Pipeline candidate | 0% (not approved) |
| Chiesi Farmaceutici | Rare bone programs | 0% (no XLH product) |
Crysvita is essentially unchallenged in XLH. No approved competitor. No biosimilar on the horizon before ~2030. This is a rare monopoly position in a growing market.
DACH Market (Germany, Austria, Switzerland)
| Metric | Value |
|---|
| DACH population | ~102 million |
| Total XLH patients | ~5,100 |
| Undiagnosed | ~2,500 -- 3,000 |
| Drug-addressable | ~2,250 -- 2,700 |
| Net revenue/patient/year (Germany AMNOG) | ~EUR 85,000 (~$90,000) |
| Ada fee/patient (10%) | ~$9,500 |
| Ada annual revenue (1 -- 5% capture) | $214K -- $1.3M |
SECTION B -- CLINICAL & DIAGNOSTIC PROFILE
Diagnostic Delay
- With family history: Mean diagnosis at 1.6 -- 2.7 years of age
- Without family history (de novo, ~30%): Mean diagnosis at 2.7 -- 4.1 years
- Adults: Often diagnosed in 20s -- 40s after years of unexplained bone pain
- Average providers seen before diagnosis: 2.3 (20% see 5+ providers)
Common Misdiagnoses
| Misdiagnosis | Why It Happens |
|---|
| Nutritional rickets | Same skeletal presentation; phosphate not checked |
| Achondroplasia | Short stature + skeletal deformity overlap |
| Growth hormone deficiency | Short stature workup stops at GH |
| "Growing pains" | Bone pain dismissed as benign |
| Osteoarthritis (adults) | Chronic pain, joint stiffness attributed to age |
Can Ada identify XLH? YES -- HIGH CONFIDENCE. XLH presents with a distinctive symptom constellation (bowed legs + short stature + dental issues + bone pain) that Ada's clinical reasoning engine can flag. Ada already covers XLH in its rare disease differential.
Ada Surface Ability: 8/10
SECTION C -- COMMERCIAL & STRATEGIC SIGNALS
- New CEO Abdul Mullick (March 2026) -- former Genzyme Rare Disease VP. Built his career on patient finding.
- 83% of diagnosed German pediatric XLH patients already on Crysvita -- conversion is done. Patient finding IS the growth lever.
- US orphan drug exclusivity expired April 2025 -- urgency to maximize patient capture
- Crysvita = 30-35% of company revenue. They cannot afford it to plateau.
- Delivered to ~7,000 patients across 52 countries -- they track patient numbers as a KPI
Company Motivation: 10/10
SECTION D -- PATIENT FINDER OPPORTUNITY
Crysvita Total Annual Ada Revenue (All Markets, Base Case 3%)
$8.0M / year
Range: $2.6M (conservative) to $15.1M (optimistic)
Pitch Hook: "83% of your diagnosed German pediatric XLH patients are already on Crysvita. Your growth is no longer about conversion -- it's about finding the 60% of XLH patients who don't know they have it. Ada's AI catches what GPs miss: the bowed legs + dental abscesses + bone pain constellation that screams phosphate metabolism disorder. We route them directly to your 40 German specialist centers -- or your US network. Per-patient economics: $200K/year in Crysvita revenue, $20K Ada fee. 10x ROI on day one."
Drug 2: Poteligeo (Mogamulizumab) -- CTCL
TIER 2
SECTION A -- MARKET NUMBERS
USA Market
| Metric | Value |
|---|
| CTCL incidence (US) | ~2,864 new cases/year (8.55/million) |
| Total living CTCL patients | ~16,000 -- 20,000 |
| Undiagnosed/misdiagnosed | ~5,000 -- 8,000 (median 3-year delay) |
| Drug-addressable (relapsed/refractory 2L+) | ~1,250 -- 2,400 |
| Net revenue per patient/year | ~$120,000 |
| Ada fee per patient (10%) | $12,000 |
Ada Revenue Scenarios (USA)
| Capture Rate | Patients Found/Year | Annual Ada Revenue |
|---|
| 1% | 13 -- 24 | $150K -- $288K |
| 3% | 38 -- 72 | $450K -- $864K |
| 5% | 63 -- 120 | $750K -- $1.4M |
SECTION B -- CLINICAL & DIAGNOSTIC PROFILE
- Diagnostic delay: Median 3 years (up to 6+ years documented)
- Key misdiagnoses: Eczema, psoriasis, contact dermatitis, tinea
- Ada surface ability: Can flag treatment-resistant skin lesion patterns, but diagnosis requires biopsy
Ada Surface Ability: 6/10 -- Ada can shorten the diagnostic odyssey but cannot replace histopathology. Value is in routing persistent "eczema" cases to dermato-oncology faster.
SECTION D -- ASSESSMENT
| Metric | Score |
|---|
| Ada Surface Ability | 6/10 |
| Company Motivation | 7/10 |
| Overall Fit Score | 6.5/10 |
Pitch Hook: "Your CTCL patients spend 3 years being treated for eczema they don't have. Ada flags the treatment-resistant skin pattern and routes to dermato-oncology for biopsy. Every year of delay means disease progression beyond Poteligeo's sweet spot."
Drug 3: Lenmeldy / Libmeldy (Atidarsagene Autotemcel) -- MLD
TIER 3
SECTION A -- MARKET NUMBERS
| Metric | USA | DACH |
|---|
| MLD prevalence | ~2,500 total patients | ~500 -- 700 |
| Birth incidence | 36 -- 90 new cases/year | 10 -- 25/year |
| Undiagnosed at any time | ~500 -- 1,000 | ~100 -- 200 |
| Drug-addressable (pre/early symptomatic) | ~50 -- 150 | ~10 -- 25 |
| Price (one-time gene therapy) | $4,250,000 | ~EUR 2,400,000 |
| Ada fee per patient (10%) | $382,500 | EUR 240,000 |
Critical limitation: Lenmeldy is only effective in pre-symptomatic or early symptomatic patients. By the time symptoms are recognized, it is often too late. The drug-addressable undiagnosed pool is extremely small.
SECTION D -- ASSESSMENT
| Metric | Score |
|---|
| Ada Surface Ability | 4/10 |
| Company Motivation | 6/10 |
| Overall Fit Score | 4.5/10 |
Pitch Hook: "At $4.25M per treatment, finding one additional pre-symptomatic patient per year justifies the entire partnership. Every month of delayed MLD diagnosis is a month of irreversible neurological damage -- and a patient who falls outside Lenmeldy's treatment window."
Drugs Not Recommended for Patient Finder
| Drug | Condition | Tier | Reason |
|---|
| Ziftomenib (KOMZIFTI) |
AML (NPM1-mutated) |
NO |
AML is diagnosed acutely in hospital settings. No underdiagnosis problem. Molecular subtyping happens at diagnosis. Wrong fit for Patient Finder. |
| Rocatinlimab |
Atopic Dermatitis |
NO |
Not yet approved (submission H1 2026). Mass-market condition with no underdiagnosis problem. 16.5M US adults already diagnosed with AD. Wrong fit. |
| Fasenra |
Severe eosinophilic asthma |
N/A |
Royalty-only income. AstraZeneca markets. No commercial lever. |
| G-Lasta, Duvroq, Nesp, PHOZEVEL |
Various (Japan-only) |
N/A |
Japan-only products. Declining or licensed. Not rare disease. Not addressable by Ada Patient Finder. |
Strategic Recommendation: Deal Structure
Phase 1: Germany Pilot (Months 1 -- 6)
| Element | Detail |
|---|
| Focus | Crysvita / XLH patient finder |
| Centers | 5 pilot: Hamburg UKE, Charite Berlin, Bochum, Munchen LMU, Hannover MHH |
| Investment | EUR 75K setup + EUR 2/assessment |
| Success criteria | 3+ new XLH diagnoses attributable to Ada pathway |
Phase 2: US Launch (Months 6 -- 12)
| Element | Detail |
|---|
| Focus | Crysvita / XLH at 8 -- 12% of first-year revenue model |
| Commercial sponsor | Steve Schaefer, President North America |
| Projected Year 1 Ada revenue | $1.6M -- $4.9M |
Phase 3: Global + Portfolio Expansion (Months 12 -- 24)
| Element | Detail |
|---|
| Focus | DACH full rollout, UK, France, Japan; add Poteligeo/CTCL and Lenmeldy/MLD |
| Projected annual Ada revenue | $5M -- $15M |
Total Kyowa Kirin Partnership Value at Maturity
$3.2M -- $19.9M / year
Base case: $9.7M annual recurring revenue to Ada
Key Contacts
| Name | Role | Relevance |
|---|
| Abdul Mullick, Ph.D. | CEO (as of March 2026) | Former Genzyme Rare Disease VP; launched Crysvita in EMEA. Rare disease patient finding is his career. |
| Steve Schaefer | President, North America | P&L owner for US Crysvita and Poteligeo. Commercial decision-maker. |
| Yoshifumi Torii | Chief Strategy Officer | Global product strategy. Portfolio-level partnership decisions. |
| Hiroshi Sonekawa | Head of Sales & Marketing | Japan market. Potential for DACH-proven model export to Japan. |